查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2070367

個人化醫療市場規模、佔有率、成長、全球產業分析、區域洞察及2026-2034年預測

Personalized Medicine Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 174 Pages | 商品交期: 2-3個工作天內

價格

個性化醫療市場的成長要素

全球個人化醫療市場預計在2025年達到2,144.4億美元，並從2026年的2,338.7億美元成長至2034年的5,870.2億美元，預測期內複合年成長率（CAGR）為12.19%。基因組檢測、伴隨診斷、基於生物標記的療法以及人工智慧驅動的臨床決策支援系統的日益普及，推動了該市場的快速擴張。個人化醫療使醫療專業人員能夠根據患者的基因、分子和臨床特徵最佳化治療方案，從而改善治療效果並減少不利事件。

憑藉強大的基因組分析基礎設施、標靶治療的廣泛應用以及先進的醫療保健系統，預計到 2025 年，北美將引領市場，佔 39.11% 的市場佔有率。

市場趨勢

個人化醫療產業最顯著的趨勢之一是標靶治療的日益普及。醫療服務提供者正逐漸從傳統的、千篇一律的治療方法轉向基於生物標記的療法。伴隨診斷和分子譜分析技術的擴展，正幫助醫生識別適合特定治療的患者，尤其是在腫瘤領域。這一趨勢正促使製藥公司加大對精準藥物研發和標靶治療解決方案的投資。

市場促進因素

慢性病和遺傳性疾病盛行率增加

癌症、心血管疾病、糖尿病和呼吸系統疾病等慢性疾病負擔日益加重，推動了對個人化醫療解決方案的需求。此外，基因測序技術的進步使得罕見疾病和遺傳性疾病的早期診斷成為可能。根據美國國立衛生研究院（NIH）2025年發布的數據，罕見疾病影響著約2500萬至3000萬美國人，凸顯了對個人化診斷和治療方法日益成長的需求。

市場限制因素

治療費用高昂

儘管市場成長潛力巨大，但個人化醫療的高成本也帶來了許多挑戰。標靶生技藥品、基因療法和精準腫瘤藥物等先進療法通常需要昂貴的分子檢測和伴隨診斷。這些成本會限制病患的就醫途徑，並造成保險報銷的難題，進而減緩個人化醫療在整個醫療體系中的普及。

市場機遇

加大研發投入

對精準醫療研究投入的增加正在創造巨大的成長機會。基因組研究、生物標記發現、人工智慧驅動的醫療解決方案以及臨床試驗的資金投入正在拓展開發平臺。這些投資正推動個人化醫療從腫瘤學領域擴展到循環系統醫學、神經病學、罕見病學和預防醫學等領域。

市場挑戰

資料隱私和安全問題

個人化醫療高度依賴基因組和臨床數據，因此隱私和網路安全至關重要。人工智慧驅動的分析平台和資料共用網路的日益普及，增加了未授權存取和資料外洩的風險。因此，醫療機構和技術提供者必須在安全資料管理和合規性方面投入大量資金。

區域分析

北美繼續保持其領先區域市場的地位，預計2025年市場規模將達到837.7億美元。美國市場預計在2026年將達到835.6億美元。在政府主導的基因組學計畫的推動下，歐洲預計將以10.54%的複合年成長率成長。亞太地區預計2026年將達到620.5億美元，主要得益於中國、日本、印度、韓國和新加坡等國醫療現代化和精準醫療領域的投資。印度的個人化醫療市場預計在2026年將達到66.9億美元。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 個人化醫療的技術進步
  • 主要疾病盛行率（按主要國家分類，2025 年）
  • 主要國家/地區的法規和還款狀況
  • 產業重大發展動態（合併、收購、合作等）
  • 新產品發布：按主要公司分類

第5章：2021-2034年全球個人化醫療市場分析、洞察與預測

  • 市場分析、洞察與預測：按產品/服務分類。
    • 診斷和檢查
    • 治療
    • 軟體和數據分析
    • 其他
  • 市場分析、洞察與預測：按技術分類
    • 基因組學和分子檢測
    • 藥物基因體學
    • 基於生物標記的分析
    • 液態生物檢體
    • 臨床決策支援與解釋軟體
    • 其他
  • 市場分析、洞察與預測：按應用領域分類
    • 腫瘤學
    • 罕見疾病和遺傳疾病
    • 神經病學
    • 循環系統
    • 感染疾病
    • 其他
  • 市場分析、洞察與預測：按最終用戶分類
    • 醫院
    • 專科診所
    • 診斷檢查室
    • 學術研究機構
    • 製藥和生物技術公司
    • 其他
  • 分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美個人化醫療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲個人化醫療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區個人化醫療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲個人化醫療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：2021-2034年中東與非洲個人化醫療市場分析、洞察與預測

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • F. Hoffmann-La Roche Ltd
    • Myriad Genetics, Inc.
    • Thermo Fisher Scientific Inc.
    • AstraZeneca
    • Guardant Health, Inc.
    • Agilent Technologies Inc.
    • Pfizer Inc.
    • Novartis AG
    • Illumina Inc.
    • Bristol-Myers Squibb Company
Product Code: FBI100350

Growth Factors of personalized medicine Market

The global personalized medicine market was valued at USD 214.44 billion in 2025 and is projected to grow from USD 233.87 billion in 2026 to USD 587.02 billion by 2034, registering a CAGR of 12.19% during the forecast period. The market is expanding rapidly due to the increasing adoption of genomic testing, companion diagnostics, biomarker-based therapies, and AI-driven clinical decision support systems. Personalized medicine enables healthcare providers to tailor treatments according to a patient's genetic, molecular, and clinical profile, improving treatment effectiveness and reducing adverse outcomes.

North America dominated the market in 2025 with a 39.11% market share, supported by strong genomics infrastructure, widespread use of targeted therapies, and advanced healthcare systems.

Market Trends

One of the most significant trends in the personalized medicine industry is the growing adoption of targeted therapies. Healthcare providers are increasingly shifting away from traditional one-size-fits-all treatment approaches toward biomarker-guided therapies. The expansion of companion diagnostics and molecular profiling technologies is helping physicians identify suitable patients for specific treatments, particularly in oncology. This trend is encouraging pharmaceutical companies to invest heavily in precision drug development and targeted treatment solutions.

Market Drivers

Increasing Prevalence of Chronic and Genetic Diseases

The rising burden of chronic diseases such as cancer, cardiovascular disorders, diabetes, and respiratory diseases is driving demand for personalized healthcare solutions. In addition, improved genomic sequencing technologies are enabling earlier diagnosis of rare and genetic disorders. According to NIH data published in 2025, rare diseases affect approximately 25-30 million Americans, highlighting the growing need for personalized diagnostic and treatment approaches.

Market Restraints

High Treatment Costs

Despite strong growth potential, the market faces challenges related to the high cost of personalized therapies. Advanced treatments such as targeted biologics, gene therapies, and precision oncology drugs often require expensive molecular testing and companion diagnostics. These costs can limit patient access and create reimbursement challenges, slowing adoption across healthcare systems.

Market Opportunities

Rising Investment in Research and Development

Growing investments in precision medicine research are creating substantial growth opportunities. Increased funding for genomic research, biomarker discovery, AI-based healthcare solutions, and clinical trials is expanding the development pipeline. These investments are helping personalized medicine expand beyond oncology into cardiology, neurology, rare diseases, and preventive healthcare applications.

Market Challenges

Data Privacy and Security Concerns

Personalized medicine relies heavily on genomic and clinical data, making privacy and cybersecurity critical concerns. The growing use of AI-driven analytics platforms and data-sharing networks increases the risk of unauthorized access and data breaches. As a result, healthcare organizations and technology providers must invest significantly in secure data management and regulatory compliance.

Segment Analysis

By Offering

The therapeutics segment dominated the market in 2025 due to strong demand for targeted therapies and biomarker-guided treatment options. Meanwhile, the software and data analytics segment is expected to register the fastest growth with a CAGR of 15.82% during the forecast period.

By Technology

The genomics and molecular testing segment led the market in 2025 and is expected to account for 34.8% market share in 2026. Growing use of next-generation sequencing, genomic profiling, and molecular diagnostics continues to drive segment growth. The liquid biopsy segment is projected to grow at a CAGR of 13.76%.

By Application

The oncology segment held the largest market share in 2025 and is expected to represent 60.8% of the market in 2026. Rising cancer prevalence and increasing use of companion diagnostics are major growth factors. The rare and genetic diseases segment is forecast to grow at a CAGR of 15.83%.

By End User

Hospitals dominated the market in 2025 and are projected to account for 38.3% of the market in 2026, owing to their extensive use of genomic testing, biomarker analysis, and targeted therapies.

Regional Analysis

North America remained the leading regional market with a value of USD 83.77 billion in 2025. The U.S. market is expected to reach USD 83.56 billion in 2026. Europe is projected to grow at a CAGR of 10.54%, supported by government-backed genomics programs. Asia Pacific is expected to reach USD 62.05 billion in 2026, driven by healthcare modernization and precision medicine investments in China, Japan, India, South Korea, and Singapore. India's personalized medicine market is projected to reach USD 6.69 billion in 2026.

Competitive Landscape

Leading companies operating in the market include F. Hoffmann-La Roche Ltd, Myriad Genetics, Thermo Fisher Scientific, AstraZeneca, Guardant Health, Agilent Technologies, Pfizer, Novartis, Illumina, and Bristol-Myers Squibb. These companies are focusing on companion diagnostics, liquid biopsy technologies, genomic testing platforms, AI-enabled interpretation software, and precision oncology solutions to strengthen their market positions.

Conclusion

The personalized medicine market is witnessing strong growth due to increasing adoption of genomic technologies, targeted therapies, companion diagnostics, and AI-powered healthcare solutions. The market size is expected to increase from USD 214.44 billion in 2025 to USD 233.87 billion in 2026, eventually reaching USD 587.02 billion by 2034. Rising prevalence of chronic diseases, expanding research investments, and advancements in precision healthcare technologies will continue to support market expansion. Despite challenges related to treatment costs and data privacy, personalized medicine is expected to transform healthcare delivery and become a cornerstone of future medical practice worldwide.

Segmentation By Offering, Technology, Application, End User, and Region

By Offering * Diagnostics & Testing

  • Therapeutics
  • Software & Data Analytics
  • Others

By Technology * Genomics & Molecular Testing

  • Pharmacogenomics
  • Biomarker-Based Profiling
  • Liquid Biopsy
  • Clinical Decision Support & Interpretation Software
  • Others

By Application * Oncology

  • Rare & Genetic Diseases
  • Neurology
  • Cardiology
  • Infectious Diseases
  • Others

By End User * Hospitals

  • Specialty Clinics
  • Diagnostic Laboratories
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Others

By Region * North America (By Offering, Technology, Application, End User, and Country)

    • U.S.
    • Canada
  • Europe (By Offering, Technology, Application, End User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Offering, Technology, Application, End User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Offering, Technology, Application, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Offering, Technology, Application, End User, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Technological Advancements in Personalized Medicine
  • 4.2. Prevalence of Key Diseases, By Key Countries/Regions, 2025
  • 4.3. Regulatory & Reimbursement Scenario, By Key Countries/Regions
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)
  • 4.5. New Product Launches, By Key Players

5. Global Personalized Medicine Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Offering
    • 5.1.1. Diagnostics & Testing
    • 5.1.2. Therapeutics
    • 5.1.3. Software & Data Analytics
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Technology
    • 5.2.1. Genomics & Molecular Testing
    • 5.2.2. Pharmacogenomics
    • 5.2.3. Biomarker-Based Profiling
    • 5.2.4. Liquid Biopsy
    • 5.2.5. Clinical Decision Support & Interpretation Software
    • 5.2.6. Others
  • 5.3. Market Analysis, Insights and Forecast - By Application
    • 5.3.1. Oncology
    • 5.3.2. Rare & Genetic Diseases
    • 5.3.3. Neurology
    • 5.3.4. Cardiology
    • 5.3.5. Infectious Diseases
    • 5.3.6. Others
  • 5.4. Market Analysis, Insights and Forecast - By End User
    • 5.4.1. Hospitals
    • 5.4.2. Specialty Clinics
    • 5.4.3. Diagnostic Laboratories
    • 5.4.4. Academic & Research Institutes
    • 5.4.5. Pharmaceutical & Biotechnology Companies
    • 5.4.6. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Personalized Medicine Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Offering
    • 6.1.1. Diagnostics & Testing
    • 6.1.2. Therapeutics
    • 6.1.3. Software & Data Analytics
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Technology
    • 6.2.1. Genomics & Molecular Testing
    • 6.2.2. Pharmacogenomics
    • 6.2.3. Biomarker-Based Profiling
    • 6.2.4. Liquid Biopsy
    • 6.2.5. Clinical Decision Support & Interpretation Software
    • 6.2.6. Others
  • 6.3. Market Analysis, Insights and Forecast - By Application
    • 6.3.1. Oncology
    • 6.3.2. Rare & Genetic Diseases
    • 6.3.3. Neurology
    • 6.3.4. Cardiology
    • 6.3.5. Infectious Diseases
    • 6.3.6. Others
  • 6.4. Market Analysis, Insights and Forecast - By End User
    • 6.4.1. Hospitals
    • 6.4.2. Specialty Clinics
    • 6.4.3. Diagnostic Laboratories
    • 6.4.4. Academic & Research Institutes
    • 6.4.5. Pharmaceutical & Biotechnology Companies
    • 6.4.6. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Personalized Medicine Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Offering
    • 7.1.1. Diagnostics & Testing
    • 7.1.2. Therapeutics
    • 7.1.3. Software & Data Analytics
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Technology
    • 7.2.1. Genomics & Molecular Testing
    • 7.2.2. Pharmacogenomics
    • 7.2.3. Biomarker-Based Profiling
    • 7.2.4. Liquid Biopsy
    • 7.2.5. Clinical Decision Support & Interpretation Software
    • 7.2.6. Others
  • 7.3. Market Analysis, Insights and Forecast - By Application
    • 7.3.1. Oncology
    • 7.3.2. Rare & Genetic Diseases
    • 7.3.3. Neurology
    • 7.3.4. Cardiology
    • 7.3.5. Infectious Diseases
    • 7.3.6. Others
  • 7.4. Market Analysis, Insights and Forecast - By End User
    • 7.4.1. Hospitals
    • 7.4.2. Specialty Clinics
    • 7.4.3. Diagnostic Laboratories
    • 7.4.4. Academic & Research Institutes
    • 7.4.5. Pharmaceutical & Biotechnology Companies
    • 7.4.6. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Personalized Medicine Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Offering
    • 8.1.1. Diagnostics & Testing
    • 8.1.2. Therapeutics
    • 8.1.3. Software & Data Analytics
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Technology
    • 8.2.1. Genomics & Molecular Testing
    • 8.2.2. Pharmacogenomics
    • 8.2.3. Biomarker-Based Profiling
    • 8.2.4. Liquid Biopsy
    • 8.2.5. Clinical Decision Support & Interpretation Software
    • 8.2.6. Others
  • 8.3. Market Analysis, Insights and Forecast - By Application
    • 8.3.1. Oncology
    • 8.3.2. Rare & Genetic Diseases
    • 8.3.3. Neurology
    • 8.3.4. Cardiology
    • 8.3.5. Infectious Diseases
    • 8.3.6. Others
  • 8.4. Market Analysis, Insights and Forecast - By End User
    • 8.4.1. Hospitals
    • 8.4.2. Specialty Clinics
    • 8.4.3. Diagnostic Laboratories
    • 8.4.4. Academic & Research Institutes
    • 8.4.5. Pharmaceutical & Biotechnology Companies
    • 8.4.6. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Personalized Medicine Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Offering
    • 9.1.1. Diagnostics & Testing
    • 9.1.2. Therapeutics
    • 9.1.3. Software & Data Analytics
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Technology
    • 9.2.1. Genomics & Molecular Testing
    • 9.2.2. Pharmacogenomics
    • 9.2.3. Biomarker-Based Profiling
    • 9.2.4. Liquid Biopsy
    • 9.2.5. Clinical Decision Support & Interpretation Software
    • 9.2.6. Others
  • 9.3. Market Analysis, Insights and Forecast - By Application
    • 9.3.1. Oncology
    • 9.3.2. Rare & Genetic Diseases
    • 9.3.3. Neurology
    • 9.3.4. Cardiology
    • 9.3.5. Infectious Diseases
    • 9.3.6. Others
  • 9.4. Market Analysis, Insights and Forecast - By End User
    • 9.4.1. Hospitals
    • 9.4.2. Specialty Clinics
    • 9.4.3. Diagnostic Laboratories
    • 9.4.4. Academic & Research Institutes
    • 9.4.5. Pharmaceutical & Biotechnology Companies
    • 9.4.6. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Personalized Medicine Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Offering
    • 10.1.1. Diagnostics & Testing
    • 10.1.2. Therapeutics
    • 10.1.3. Software & Data Analytics
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Technology
    • 10.2.1. Genomics & Molecular Testing
    • 10.2.2. Pharmacogenomics
    • 10.2.3. Biomarker-Based Profiling
    • 10.2.4. Liquid Biopsy
    • 10.2.5. Clinical Decision Support & Interpretation Software
    • 10.2.6. Others
  • 10.3. Market Analysis, Insights and Forecast - By Application
    • 10.3.1. Oncology
    • 10.3.2. Rare & Genetic Diseases
    • 10.3.3. Neurology
    • 10.3.4. Cardiology
    • 10.3.5. Infectious Diseases
    • 10.3.6. Others
  • 10.4. Market Analysis, Insights and Forecast - By End User
    • 10.4.1. Hospitals
    • 10.4.2. Specialty Clinics
    • 10.4.3. Diagnostic Laboratories
    • 10.4.4. Academic & Research Institutes
    • 10.4.5. Pharmaceutical & Biotechnology Companies
    • 10.4.6. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of the Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. F. Hoffmann-La Roche Ltd
    • 11.2.2. Myriad Genetics, Inc.
    • 11.2.3. Thermo Fisher Scientific Inc.
    • 11.2.4. AstraZeneca
    • 11.2.5. Guardant Health, Inc.
    • 11.2.6. Agilent Technologies Inc.
    • 11.2.7. Pfizer Inc.
    • 11.2.8. Novartis AG
    • 11.2.9. Illumina Inc.
    • 11.2.10. Bristol-Myers Squibb Company

List of Tables

  • Figure 1: Global Personalized Medicine Market Revenue Breakdown (USD Billion, %) by Region, 2025 & 2034
  • Figure 2: Global Personalized Medicine Market Value Share (%), By Offering, 2025 & 2034
  • Figure 3: Global Personalized Medicine Market Value Share (%), By Technology, 2025 & 2034
  • Figure 4: Global Personalized Medicine Market Value Share (%), By Application, 2025 & 2034
  • Figure 5: Global Personalized Medicine Market Value Share (%), By End User, 2025 & 2034
  • Figure 6: Global Personalized Medicine Market Value Share (%), by Region, 2025 & 2034
  • Figure 7: North America Personalized Medicine Market Value (USD Billion), By Offering, 2025 & 2034
  • Figure 8: North America Personalized Medicine Market Value Share (%), By Offering, 2025
  • Figure 9: North America Personalized Medicine Market Value (USD Billion), By Technology, 2025 & 2034
  • Figure 10: North America Personalized Medicine Market Value Share (%), By Technology, 2025
  • Figure 11: North America Personalized Medicine Market Value (USD Billion), By Application, 2025 & 2034
  • Figure 12: North America Personalized Medicine Market Value Share (%), By Application, 2025
  • Figure 13: North America Personalized Medicine Market Value (USD Billion), By End User, 2025 & 2034
  • Figure 14: North America Personalized Medicine Market Value Share (%), By End User, 2025
  • Figure 15: North America Personalized Medicine Market Value (USD Billion), by Country, 2025 & 2034
  • Figure 16: North America Personalized Medicine Market Value Share (%), by Country, 2025
  • Figure 17: Europe Personalized Medicine Market Value (USD Billion), By Offering, 2025 & 2034
  • Figure 18: Europe Personalized Medicine Market Value Share (%), By Offering, 2025
  • Figure 19: Europe Personalized Medicine Market Value (USD Billion), By Technology, 2025 & 2034
  • Figure 20: Europe Personalized Medicine Market Value Share (%), By Technology, 2025
  • Figure 21: Europe Personalized Medicine Market Value (USD Billion), By Application, 2025 & 2034
  • Figure 22: Europe Personalized Medicine Market Value Share (%), By Application, 2025
  • Figure 23: Europe Personalized Medicine Market Value (USD Billion), By End User, 2025 & 2034
  • Figure 24: Europe Personalized Medicine Market Value Share (%), By End User, 2025
  • Figure 25: Europe Personalized Medicine Market Value (USD Billion), by Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Personalized Medicine Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Personalized Medicine Market Value (USD Billion), By Offering, 2025 & 2034
  • Figure 28: Asia Pacific Personalized Medicine Market Value Share (%), By Offering, 2025
  • Figure 29: Asia Pacific Personalized Medicine Market Value (USD Billion), By Technology, 2025 & 2034
  • Figure 30: Asia Pacific Personalized Medicine Market Value Share (%), By Technology, 2025
  • Figure 31: Asia Pacific Personalized Medicine Market Value (USD Billion), By Application, 2025 & 2034
  • Figure 32: Asia Pacific Personalized Medicine Market Value Share (%), By Application, 2025
  • Figure 33: Asia Pacific Personalized Medicine Market Value (USD Billion), By End User, 2025 & 2034
  • Figure 34: Asia Pacific Personalized Medicine Market Value Share (%), By End User, 2025
  • Figure 35: Asia Pacific Personalized Medicine Market Value (USD Billion), by Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Personalized Medicine Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 37: Latin America Personalized Medicine Market Value (USD Billion), By Offering, 2025 & 2034
  • Figure 38: Latin America Personalized Medicine Market Value Share (%), By Offering, 2025
  • Figure 39: Latin America Personalized Medicine Market Value (USD Billion), By Technology, 2025 & 2034
  • Figure 40: Latin America Personalized Medicine Market Value Share (%), By Technology, 2025
  • Figure 41: Latin America Personalized Medicine Market Value (USD Billion), By Application, 2025 & 2034
  • Figure 42: Latin America Personalized Medicine Market Value Share (%), By Application, 2025
  • Figure 43: Latin America Personalized Medicine Market Value (USD Billion), By End User, 2025 & 2034
  • Figure 44: Latin America Personalized Medicine Market Value Share (%), By End User, 2025
  • Figure 45: Latin America Personalized Medicine Market Value (USD Billion), by Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Personalized Medicine Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Personalized Medicine Market Value (USD Billion), By Offering, 2025 & 2034
  • Figure 48: Middle East & Africa Personalized Medicine Market Value Share (%), By Offering, 2025
  • Figure 49: Middle East & Africa Personalized Medicine Market Value (USD Billion), By Technology, 2025 & 2034
  • Figure 50: Middle East & Africa Personalized Medicine Market Value Share (%), By Technology, 2025
  • Figure 51: Middle East & Africa Personalized Medicine Market Value (USD Billion), By Application, 2025 & 2034
  • Figure 52: Middle East & Africa Personalized Medicine Market Value Share (%), By Application, 2025
  • Figure 53: Middle East & Africa Personalized Medicine Market Value (USD Billion), By End User, 2025 & 2034
  • Figure 54: Middle East & Africa Personalized Medicine Market Value Share (%), By End User, 2025
  • Figure 55: Middle East & Africa Personalized Medicine Market Value (USD Billion), by Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Personalized Medicine Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 57: Global Personalized Medicine Market Share (%), by Company, 2025